NTRK3 and metastatic malignant neoplasm: As reported above, the ALKA-372-001, STARTRK-1, and STARTRK-2 studies evaluated both the safety and efficacy of orally administering entrectinib to adult patients with locally advanced metastatic cancer with NTRK1, NTRK2, NTRK3, ROS1, or ALK rearrangements.